Loading...
•
Jun 30, 2023
ClearPoint Neuro Q2 2023 Earnings Report
Reported record revenue and biologics & drug delivery growth.
Key Takeaways
ClearPoint Neuro reported a record quarterly revenue of $6.0 million, a 14% year-over-year increase, driven primarily by the growth in biologics and drug delivery services.
Reported record quarterly revenue of $6.0 million, a 14% year-over-year increase.
Increased biologics and drug delivery revenue to $3.4 million, a 40% year-over-year increase.
Installed multiple new PRISM laser therapy units and continued the limited market release in the U.S.
Cash and cash equivalents totaled $26.5 million as of June 30, 2023.
Revenue by Segment
Forward Guidance
The Company reaffirms its full year 2023 revenue outlook of between $25.0 and $27.0 million.
Positive Outlook
- Accelerating revenue growth
- Adding meaningful strategic and milestone-based biologics and drug delivery agreements
- Expanding our PRISM limited market release to multiple new centers
- Executing as many as five FDA submissions directly or through partnerships for new products
- Completing the qualification of our new manufacturing clean room facility in Carlsbad, California and producing sellable product
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...